Skip to main content

Edwards Lifesciences to spin off critical-care unit, sets $1B stock buyback

Katie Szyman will be chief executive of the independent company, which is expected to generate $905 million in sales in 2023.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.